Chikunguru 2022: Dabrafenib (Tafinlar, Novartis) uye trametinib (Mekinist, Novartis) vakagamuchira kukurumidza kubvumidzwa kubva kuFood and Drug Administration yekurapwa kwevakuru nevana varwere vakura kupfuura makore matanhatu ane unre.
Chikumi 2022: Mushure memitsara miviri kana kupfuura yesystemic therapy, FDA yakapa tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) yakakurumidza kubvumidza kuvarwere vakura vane relapsed kana refractory follicular lymphoma (FL) T.
Kubvumbi 2022: The Food and Drug Administration yakabvumidza Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., kambani yeNovartis) kurapwa kwevarwere vakuru vane prostate-yakananga mem.
Kurume 2022: Nzira yekushandura CAR-T Cell therapy ine mukana wekupidigura icho chave axiom yekurapa: kuti kurapwa kunoshamisa pamabundu kunouya nekurasikirwa kwenjodzi dzakakura kune murwere.
Immunotherapy mukurapwa kwegomararaCancer CAR-NK therapy ine mwero inoshanda inosvika 73%, uye iri kutorwa mumakiriniki edzimba.Immunotherapy yakashandura nzira inorapwa nayo gomarara. Cancer immunotherapy inoparadzaniswa..